ContraVir Pharmaceuticals Inc (CTRV) Short Interest Up 127.3% in October
ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) saw a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 3,193,481 shares, a growth of 127.3% from the October 14th total of 1,405,223 shares. Currently, 6.6% of the company’s shares are short sold. Based on an average trading volume of 5,083,634 shares, the days-to-cover ratio is presently 0.6 days.
Separately, Maxim Group reiterated a “buy” rating and issued a $4.00 target price on shares of ContraVir Pharmaceuticals in a report on Thursday, October 13th.
Shares of ContraVir Pharmaceuticals (NASDAQ:CTRV) opened at 2.03 on Wednesday. The company’s market capitalization is $108.92 million. ContraVir Pharmaceuticals has a one year low of $0.76 and a one year high of $2.65. The firm has a 50-day moving average price of $1.70 and a 200-day moving average price of $1.20.
Several institutional investors have recently bought and sold shares of CTRV. Teachers Advisors Inc. boosted its position in ContraVir Pharmaceuticals by 95.2% in the second quarter. Teachers Advisors Inc. now owns 289,919 shares of the biopharmaceutical company’s stock worth $1,102,000 after buying an additional 141,368 shares during the last quarter. Vanguard Group Inc. boosted its position in ContraVir Pharmaceuticals by 8.7% in the second quarter. Vanguard Group Inc. now owns 915,369 shares of the biopharmaceutical company’s stock worth $952,000 after buying an additional 73,135 shares during the last quarter. Finally, Prospera Financial Services Inc boosted its position in ContraVir Pharmaceuticals by 8.5% in the third quarter. Prospera Financial Services Inc now owns 193,800 shares of the biopharmaceutical company’s stock worth $207,000 after buying an additional 15,250 shares during the last quarter.
About ContraVir Pharmaceuticals
ContraVir Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of virology drugs to treat diseases of unmet needs, such as herpes zoster and hepatitis B (HBV). It is developing targeted antiviral therapies with over two drug candidates in clinical studies. Its FV-100 is an orally available, small molecule, nucleoside analogue pro-drug of CF-1743 that it is developing for the treatment of herpes zoster, which is an infection caused by the reactivation of varicella zoster virus or VZV.
Receive News & Stock Ratings for ContraVir Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.